Pliant Therapeutics, Inc. (PLRX) Stock

Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, dedicated to advancing novel therapies for the treatment of fibrosis and related diseases across the United States. At the forefront of its development efforts is PLN-74809, a promising oral small-molecule dual selective inhibitor targeting av�6 and av�1 integrins. This lead candidate is currently undergoing evaluation in three Phase 2a clinical trials.

In addition to PLN-74809, Pliant Therapeutics is actively progressing PLN-1474, another small-molecule selective inhibitor designed specifically to target av�1 integrins. This candidate has completed Phase 1 clinical trials and is aimed at addressing liver fibrosis associated with nonalcoholic steatohepatitis (NASH), a condition of growing concern worldwide.

Beyond its leading candidates, Pliant Therapeutics is engaged in advancing two preclinical integrin-based programs. These initiatives encompass an oncology program and the development of an allosteric agonistic monoclonal antibody targeting an undisclosed integrin receptor. This innovative approach holds promise for treating muscular dystrophies, including Duchenne muscular dystrophy.

Founded in 2015, Pliant Therapeutics has rapidly positioned itself as a pioneer in fibrosis research, leveraging its deep expertise and strategic location within the biotechnology hub of South San Francisco. The company's commitment to advancing therapeutic solutions for challenging diseases underscores its dedication to making significant contributions to patient care and advancing the field of biopharmaceuticals.